Abstract Background The recently developed TIGER endoscopy score was established to reliably describe disease severity as it can be utilized for both Ulcerative Colitis (UC) and Crohn’s (CD) patients.1The aim of this prospective study assess the score’s ability predict UC CD patient outcomes including biologic steroid use. Methods A cohort 78 patients with (n=40) (n=38) were included in a 52-we...

Background: Inflammatory bowel disease (IBD), with its 3 subgroups: Crohn’s disease (CD), ulcerative colitis (UC), and indeterminate colitis (IC), is a chronic relapsing inflammatory disorder of the gastrointestinal (GI) tract. Medication adherence is particularly problematic in pediatric IBD. To date this has not been studied in the Middle East. Objectives: The aim of this study was to describ...

BACKGROUND AND OBJECTIVES To present our experience with a single-incision laparoscopic total colectomy, along with a literature review of all published cases on single-incision laparoscopic total colectomy. METHODS A total of 22 cases were published between 2010 and 2011, with our patient being case 23. These procedures were performed in the United States and United Kingdom. Surgical proced...

Abstract Background The coexistence of immune-mediated diseases and non-pharmacological immunosuppression states are rare might determine the natural history disease therapeutic decisions physician. IBD guidelines recommend screening for human immunodeficiency virus (HIV) before starting immunosuppressive treatment, but data on impact HIV infection its management in era biological drugs scarce....

Abstract Background Bowel urgency is a common and disruptive symptom of ulcerative colitis (UC), distinct from stool frequency (SF) rectal bleeding (RB).1 Information limited on the relationships between bowel clinically meaningful improvement (CMI), remission, SF remission or RB in Patient Global Rating Severity Change (PGRS/PGRC) scores patients with moderately-to-severely active UC. We estim...

Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. The long-term, Phase 3b/4 RIVETING study (NCT03281304) assessed efficacy and safety tofacitinib dose reduction from 10 mg twice daily (BID) maintenance therapy to 5 BID in patients (pts) stable remission.1 We present a final analysis after ≥30 months treatment. Methods was d...